News

NeuVax is a peptide immunotherapy for the prevention of cancer recurrence and is Galena’s lead development agent in multiple ongoing and planned clinical trials. Once issued, the patent

Cortex is developing dronabinol (D9-tetrahydrocannabinol), a cannabinoid, for the treatment of obstructive sleep apnea (OSA), the most common form of sleep apnea. Cortex previously conducted a 21 day,

The combination creates one of the world’s fastest-growing specialty pharmaceutical companies, with annual revenues of more than $15 billion anticipated for 2015. In conjunction with the close of

In the study a statistically significant greater proportion of rifaximin treated subjects (as compared to placebo) responded to repeat treatment as assessed by the composite primary endpoint of

Founders Fund and Max Levchin, a PayPal co-founder, led this latest financing along with investment from Schooner Capital. The company also announced the release of its first product:

Lemtrada, a monoclonal antibody that selectively targets CD52, has been approved by ANMAT to treat adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined by

The investigational vaccine is being co-developed by GlycoVaxyn AG and Janssen Pharmaceuticals Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The first-in-human clinical study

So far, WILEX has completed many clinical studies with Mesupron in different indications, including two Phase II proof of concept trials for pancreatic cancer and metastatic breast cancer.

Eisai’s E6201 is a dual-targeted FLT3 and MEK inhibitor, which has completed a PhaseI clinical trial showing preliminary antitumor activity and an acceptable safety profile. Building on a